Literature DB >> 11978928

Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.

S Mehandru1, R L Smith, G S Sidhu, N Cassai, C P Aranda.   

Abstract

The case history is described of an elderly man with rheumatoid arthritis receiving treatment with sulfasalazine and the cyclooxygenase-2 inhibitor celecoxib who presented with severe shortness of breath, cough, and decreased exercise tolerance. The chest radiograph showed unilateral alveolo-interstitial infiltrates and a biopsy specimen of the lung parenchyma showed changes consistent with acute eosinophilic pneumonia. Antibiotic treatment was unsuccessful, but treatment with steroids and discontinuation of sulfasalazine and celecoxib resulted in a marked clinical improvement confirmed by arterial blood gas analysis. The condition may have developed as an adverse reaction either to sulfasalazine or to celecoxib, although hypersensitivity to the latter has not previously been reported.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978928      PMCID: PMC1746324          DOI: 10.1136/thorax.57.5.465

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  3 in total

1.  Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.

Authors:  Deborah Layton; Lynda V Wilton; Saad A W Shakir
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

2.  Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis.

Authors:  Bahar Ulubaş; Günşah Sahin; Caner Ozer; Ozlem Aydin; Eylem Ozgür; Demir Apaydin
Journal:  Clin Rheumatol       Date:  2004-02-24       Impact factor: 2.980

3.  Suspected fibrin glue-induced acute eosinophilic pneumonia after pulmonary resection: A case report.

Authors:  Nobutaka Kawamoto; Riki Okita; Masataro Hayashi; Masanori Okada; Kosuke Ito; Eiji Ikeda; Hidetoshi Inokawa
Journal:  Thorac Cancer       Date:  2021-05-25       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.